MedPath

Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer

Not Applicable
Conditions
pancreatic ductal adenocarcinoma
Registration Number
JPRN-UMIN000034453
Lead Sponsor
Tochigi Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
166
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with macroscopically positive resection margin or distant metastasis were excluded. Patients with Pre-CA 19-9 < 5 U/ml were excluded. CA 19-9 values were not included in the analysis if serum total bilirubin was >2.0 mg/dl at the time of assay.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath